ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Meropenem

Also written as “meropenem” and “Meropenem plus vaborbactam”.

Its studies are mostly in Sepsis · Enterocolitis, Necrotizing · Bacterial Infections · Pancreatitis · Cellulitis, led by 2 companies.

Drug pageMeropenem: every studyAll 62 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 27, 20035 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer40 open or runningphase 4since May 27, 2003May 27, 2003none ahead
The Emmesits history only10 open or runningphase 2since Feb 20, 2008Feb 20, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 27, 2003First study: phase 4 study in Pancreatitis, Acute NecrotizingFirst studyNCT00061438 · 240 enrolled · United States, Canada
  2. Apr 25, 20062 phase 4 studiesNCT00318552, NCT00318994
  3. Feb 6, 2008Phase 3 study in CellulitisNCT00619710 · 1,000 enrolled

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial penicillin-binding protein inhibitor”ChEMBL 37, by rule

Studies

All 4 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00619710Cellulitis3CompletedDec 20031,000
NCT00318994Pancreatitis · Colombia4CompletedSep 20056
NCT00318552Sepsis · Hungary4CompletedJun 2006160
NCT00061438Pancreatitis, Acute Necrotizing · United States, Canada4CompletedDec 2004240

How it is read

Names in the registry

  • “Meropenem”, 6 entries
  • “meropenem”, 3 entries
  • “Meropenem plus vaborbactam”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.